CASE PRESENTATION {#s1}
=================

A 65-yr-old male presented with a 2-wk history of jaundice preceded by a 3-wk history of abdominal discomfort and diarrhea, accompanied by a 15--20-pound weight loss in 1 mo. He had a prior medical history of morbid obesity and sleep apnea. Initial computed tomography (CT) revealed dilation of both the common bile duct and the pancreatic duct and a poorly defined hyperdense region in the pancreatic head. Upon referral to a gastroenterologist, the patient underwent endoscopic retrograde cholangiopancreatography with sphincterotomy. Brush cytology revealed pancreatic adenocarcinoma cells, and the patient subsequently underwent a Whipple procedure to remove the tumor. His tumor was moderately to poorly differentiated pancreatic ductal adenocarcinoma, T3N1, Stage IIB (tumor growing outside of the pancreas but not into major blood vessels/nerves, and in 3/21 lymph nodes). Given his relatively poor prognosis, he was offered adjuvant chemotherapy. Two months after the Whipple procedure, he started gemzar and abraxane that was continued for five cycles and received his last cycle with gemzar only because of weakness and anemia. Both the patient and treating physician decided on the doublet of gemzar and abraxane because of a better toxicity profile, simpler logistics, and improved clinical outcome in a metastatic setting. The patient was subsequently referred to radiation oncology for adjuvant chemoradiation therapy; however, a restaging CT scan performed 5 mo after adjuvant treatment showed multiple liver metastases, and therefore he did not receive any radiation treatment. A liver biopsy performed at the time of disease recurrence was positive for metastatic pancreatic adenocarcinoma, indicating that despite the initial staging of the patient\'s tumor as stage IIB it is likely that he had distant metastasis. He received a second line of combinatorial chemotherapy (5-FU/liposomal irinotecan) for 2 mo and third-line chemotherapy with FOLFOX (5-FU and oxaliplatin) with progression of his disease. His disease was monitored by serum tumor marker carbohydrate antigen (CA) 19-9 throughout his treatment. In addition, the patient underwent CT monitoring of the chest, abdomen, and pelvis. Based on his clinical status the patient was eligible for tumor genome profiling by the IBM Watson Health sponsored, New York Genome Center (NYGC) Cancer Alliance pilot study. The study was approved by Stony Brook University and Biomedical Research Alliance of New York institutional review boards.

METHODS {#s2}
=======

Whole-Genome, Whole-Exome, and Transcriptome Sequencing {#s2a}
-------------------------------------------------------

The specimens were received as OCT (Optimal Cutting Temperature compound)-embedded tumor tissue from a liver metastasis and peripheral blood as normal. DNA and RNA purification, extraction, and library preparations were performed as previously reported ([@MCS004424WRZC20]). Whole-genome DNA sequencing was performed on the Illumina HiSeq X 2 × 150 bp paired-end sequencing (Illumina). The libraries were loaded at a 2:1 tumor:normal ratio to reach coverage of 110× (average read depth) for the tumor sample and 64× for the normal sample. As part of the study, whole-exome DNA sequencing was additionally performed using SureSelectXT Human All Exon V6 + COSMIC capture kit (Agilent) and 2 × 125 bp paired-end sequencing was performed on a Illumina HiSeq 2500 instrument to reach an average read depth of 238× for the tumor and 105× for the normal. The RNA sample was prepared using an mRNA protocol as previously reported ([@MCS004424WRZC20]), and the library was sequenced on the Illumina HiSeq 2500 2 × 125 bp rapid run platform obtaining approximately 57 million reads. Somatic single-nucleotide variants (SNVs), insertions and deletions (indels), structural variants (SVs), copy-number variants (CNVs), and fusions were called from whole-genome and transcriptome sequencing as previously reported ([@MCS004424WRZC19]). Whole-exome sequencing was used only to identify SNVs and indels. RNA sequencing was used to call fusions and confirm the expression of SNVs and indels.

Microarray Genotyping {#s2b}
---------------------

Genotyping was performed as an internal quality control measure and to determine copy number (ploidy) and tumor content (purity). Extracted DNA was normalized, denatured, and neutralized. After an overnight amplification step, DNA was fragmented, precipitated, resuspended, and hybridized to Illumina HumanOmni2.5M BeadChips (Illumina WG-313-2511). BeadChips were loaded onto the Illumina HiScan microarray scanner, which yields fluorescence intensity data files that are interpreted in the context of biological information about the SNVs on the Bead Chips to generate genotype calls. Copy number, tumor purity, and ploidy are calculated using the ASCAT tool ([@MCS004424WRZC17]).

Sanger Sequencing {#s2c}
-----------------

DNA derived from tumor was independently used as a template to PCR amplify BRAF exon 12 using the following primer sequences: exon 12F 5′-AATGGTATGGAGTTAGGGCTATG-3′ and exon 12R 5′-CTGGGAACCAGGAGCTAATAAA-3′. The resulting 258 bp product was purified using ExoSAP-IT (Thermo Fisher Scientific, 78201.1.ML) and Sanger sequenced using BigDye Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific 4337455). The samples were loaded onto the ABI 3500 Dx machine and AB1 files were analyzed using Mutation Surveyor version 5.0 (SoftGenetics).

Variant Interpretation {#s2d}
----------------------

Initial variant detection was performed as part of the NYGC whole genome and transcriptome clinical assay ([@MCS004424WRZC20]). SNV and indels were annotated via snpEff, snpSift ([@MCS004424WRZC3]), and GATK VariantAnnotator using annotation from ENSEMBL, COSMIC ([@MCS004424WRZC16]), Gene Ontology, and 1000 Genomes. All variants were annotated based on an in-house clinical classification system in which variants in targetable and COSMIC cancer census ([@MCS004424WRZC5]) genes were identified and prioritized. Initial matching of each variant to drug(s) was performed by (i) identifying the tumor-specific gene variants, relative to normal germline DNA, based on SNV, CNV, and RNA sequencing data and (ii) matching to the expert-curated NYGC drug-to-gene database (June 2016). Our internal drug-to-gene database was assembled by manual curation of publicly available data from the National Comprehensive Network (NCCN; <https://www.nccn.org/>), the U.S. Food and Drug Administration (<https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs>), Clinical Interpretations of Variants in Cancer (CIVIC) (civic.genome.wustl.edu), Precision Cancer Therapy-MD Anderson (<https://pct.mdanderson.org/>), OncoKB (oncokb.org), canSar (<https://cansar.icr.ac.uk>), Pharmacogenomics Knowledgebase (PharmGKB) ([www.pharmgkb.org](www.pharmgkb.org)), ClinicalTrials.gov (clinicaltrials.gov), and directed literature searches.

RESULTS {#s3}
=======

Whole-genome sequencing revealed a *BRAF* in-frame deletion of five amino acids within the kinase domain ([Table 1](#MCS004424WRZTB1){ref-type="table"}). This deletion was also detectable by whole-exome sequencing, transcriptome sequencing and was confirmed by Sanger sequencing ([Fig. 1](#MCS004424WRZF1){ref-type="fig"}A,B). Activating mutations in the KRAS signaling pathway are common in pancreatic cancers, with ∼90% of pancreatic ductal adenocarcinomas (PDACs) containing mutations in *KRAS* ([@MCS004424WRZC10]; [@MCS004424WRZC18]). In one large cohort, *BRAF* mutations were detected in 1.4% of pancreatic carcinomas and were mutually exclusive with *KRAS* mutations ([@MCS004424WRZC6]). About half of these were deletions in the β3-αC loop of five residues, including the Asn486_Pro490 deletion seen in this specimen. The deletion potentially shifts the αC helix into an active conformation such that the catalytic residue Lys483 of β3 forms a salt bridge interaction with Glu501 of the αC helix ([Fig. 1](#MCS004424WRZF1){ref-type="fig"}C). In preclinical studies this variant was shown to be sensitive to the BRAF inhibitor dabrafenib and a sorafenib-related compound, but resistant to vemurafenib in cell line assays ([@MCS004424WRZC6]). BRAF inhibitor sensitivity is lost in longer term assays, although the mutant remains sensitive to MEK inhibitors in the same time-frame. A dabrafenib/trametinib combination phase I/II clinical trial (NCT01989585) was identified.

![(*A*) BRAF Chr 7:140477836 (c.1457_1471delATGTGACAGCACCTA_p.Asn486_Pro490del) as visualized in whole-genome sequencing (*top* track, WGS-Tumor), whole-exome sequencing (*center* track, WES-Tumor), and blood normal sample (*lower* track, Normal). (*B*) Sanger sequencing electropherogram confirming the BRAF ΔNVTAP variant. (*C*) Location of the deletion variant in BRAF protein (red) and residues involved in a potential salt bridge (green) (PDB:1UWH). (*D*) CA 19-9 marker serum levels (units/mL) over time. (*E*) Patient CT scan of pre- (*left*) and post- (*right*) dabrafenib treatment demonstrating decrease in the hepatic metastatic tumor burden posttreatment.](MCS004424Wrz_F1){#MCS004424WRZF1}

###### 

Genomic findings

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene       CHR:POS       HGVS cDNA                                    HGVS protein                        Variant type          Predicted effect                                                                                     Variant allele frequency (Alt/Ref allele read count)   Read depth of variant
  ---------- ------------- -------------------------------------------- ----------------------------------- --------------------- ---------------------------------------------------------------------------------------------------- ------------------------------------------------------ ------------------------------
  *BRAF*     7:140477836   NM_004333.4:c.1457_1471del ATGTGACAGCACCTA   NP_004324.2: p.Asn486\_ Pro490del   In frame deletion     Activating mutation ([@MCS004424WRZC6])                                                              WGS: 66% (68/35)\                                      WGS: 103×\
                                                                                                                                                                                                                                       WES: 64% (77/44)                                       WES: 121×

  *CDKN2A*   9:21971120    NM_001195132.1:c.238C\>T                     NP_001182061.1: p.Arg80^a^          Nonsense              Variant of uncertain significance likely loss of function ([@MCS004424WRZC14]; [@MCS004424WRZC21])   WGS: 62% (48/29)\                                      WGS: 77×\
                                                                                                                                                                                                                                       WES: 66% (165/84)                                      WES: 249×

  *TP53*     17:7579380    NM_000546.5:c.299_306del AGAAAACC            NP_000537: p.Gln100Leufs Ter46      Frame shift           Variant of uncertain significance likely oncogenic ([@MCS004424WRZC2])                               WGS: 56% (42/33)\                                      WGS: 75×\
                                                                                                                                                                                                                                       WES: 52% (82/76)                                       WES: 158×

  *SMAD4*    18q21.2       NM_005359.5                                  NM_005350.1                         Homozygous deletion   Loss of function ([@MCS004424WRZC9])                                                                 Copy-number log~2~(T/N) = −1.624                       WGS (18q mean coverage): 96×
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Termination (stop) codon (https://www.hgvs.org/mutnomen/standards.html).

Additional variants of clinical significance identified were a *CDKN2A* stop codon, a *TP53* frameshift mutation and homozygous loss of *SMAD4* ([Table 1](#MCS004424WRZTB1){ref-type="table"}). Inactivating mutations in *CDKN2A*, *TP53*, and *SMAD4* occur in \>50% of pancreatic cancers ([@MCS004424WRZC18]; [@MCS004424WRZC11]). The *CDKN2A* mutation likely affected all copies of *CDKN2A* based on variant allele frequency of 62% and an estimated tumor purity of 61%, which would result in complete loss of *CDKN2A* function. *CDKN2A* (p16/INK4a) binds to CDK4/6 regulating the cell cycle. Loss of *CDKN2A* can result in activation of CDK4 that in turn phosphorylates RB1. RB1-P can no longer inhibit E2F transcription factor resulting in cellular proliferation. Combinatorial therapy with CDK4/6 inhibitors, palbociclib and ribociclib, would be a potential therapeutic option ([@MCS004424WRZC7]). A *TP53* early frameshift mutation, also likely to be homozygous ([Table 1](#MCS004424WRZTB1){ref-type="table"}), would be predicted to lead to loss of p53 growth-inhibitory effects. The whole-genome copy-number profile suggested a highly aberrant genome with tumor ploidy of 2.46. *SMAD4* two-copy homozygous loss at chromosome position 18q21.2 (log~2~(T/N) = −1.624) was detected resulting in possible loss of function of the tumor suppressor. SMAD4 has been identified as a key regulator in prostate adenocarcinoma progression ([@MCS004424WRZC4]).

SUMMARY {#s4}
=======

A patient with advanced pancreatic cancer was enrolled in the NYGC Cancer Alliance pilot study for tumor genome sequencing, which revealed somatic mutations in *BRAF, TP53*, *CDKN2A*, and a focal deletion of *SMAD4*. The case was presented at two molecular tumor boards---one at NYGC with scientists and physicians conducting the sequencing pilot study and one at Stony Brook Medical Center with representatives from clinical oncology and pathology. Given no further standard-of-care options and no nearby therapeutic clinical trials, the board recommended participation in the NCI-MATCH clinical trial. However, because the patient did not have the standard *BRAF* V600E mutation, he was not eligible for NCI-MATCH. The board decided that the demonstrated clinical utility of BRAF inhibition and combined BRAF/MEK inhibition in phase II clinical results in *BRAF*-mutant melanoma made a compelling case for trying this combination in this patient. Subsequently, the combination of these drugs was approved for *BRAF*-mutant lung, melanoma, and thyroid cancers ([@MCS004424WRZC12]; [@MCS004424WRZC13]; [@MCS004424WRZC15]). We therefore requested and obtained both the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib from Novartis for off-label use. Because of the patient\'s poor performance status and liver dysfunction, the BRAF inhibitor dabrafenib was started at 75 mg po bid and gradually increased to full dose. The patient\'s overall clinical condition improved dramatically with dabrafenib. Since initiating therapy the patient had showed a clinical response in palpable liver disease, levels of the serum tumor marker CA 19-9 dropped immediately after treatment ([Fig. 1](#MCS004424WRZF1){ref-type="fig"}D), and a subsequent CT scan revealed significant decrease in the size of both primary (not shown) and hepatic metastatic lesions ([Fig. 1](#MCS004424WRZF1){ref-type="fig"}E). The patient responded well for ∼4 mo with no significant side effects but was noted to have increasing abdominal pain and weakness. With rising CA 19-9, trametinib was added but the patient did not respond to further therapy. Eventual CT scans showed progression of disease and the patient decided on palliative and hospice care. A second liver biopsy to better understand the potential mechanism of escape post--dabrafenib treatment was not possible because of the patient\'s deteriorating clinical condition. Somatic *BRAF* mutations occur in 3% of pancreatic cancers and are often inversely correlated with KRAS variants ([@MCS004424WRZC1]; [@MCS004424WRZC8]). The ΔNVTAP *BRAF* has been observed in \<0.5% pancreatic cases ([@MCS004424WRZC8]). Here, we show evidence of partial response and direct targetability of dabrafenib in a patient with an identified BRAF in-frame pathogenic deletion that had previously only been described in preclinical studies.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

The data (in vcf format) for this case can be obtained from ftp://ftp.nygenome.org/CA/9/ or by request to the corresponding author until it is made available in the EGA-archive.org public repository (ega-box-1298) as part of the larger study submission. The BRAF variant has been deposited into the ClinVar database (<https://www.ncbi.nlm.nih.gov/clinvar/>) under accession number VCV000666267.1.

Ethics Statement {#s5b}
----------------

This study was reviewed and approved by the Biomedical Research Alliance of New York Institutional Review Board (IRB), Rockefeller University and the Stony Brook University IRB. Written consent for genomic sequencing was obtained. The protocol allowed for the return of research sequencing results after confirmation in a clinical laboratory.

Acknowledgments {#s5c}
---------------

We thank the patient for participation in this study and the research use of his specimens.

Author Contributions {#s5d}
--------------------

K.O.W. provided data analysis, interpretation, and initial drafting and revision of the final manuscript; S.R. provided data analysis and interpretation; M.O.F. designed the study, acquired data, and revised the manuscript; K.A. performed data analysis; M.S. and H.G. performed data analysis and revised the manuscript; V.F. and D.M. performed laboratory protocols, data acquisition, and data analysis and revised the manuscript; E.D. performed data analysis and laboratory protocols; D.K. performed data and quality review; A.R.C. performed the radiological analysis and interpretation; V.V.M. and V.J. performed data interpretation and revised the manuscript; R.B.D. conceived and designed the study, led the tumor board, performed data interpretation, and revised the manuscript; S.P. performed data interpretation and the initial drafting and revision of the manuscript; and M.C. performed data acquisition, patient care, interpretation, and initial drafting and revision of the manuscript.

Funding {#s5e}
-------

This study was supported in part by a grant from the IBM corporation (IBM Watson Health) to the New York Genome Center, New York Genome Center philanthropic funds and Rockefeller University grant \#UL1 TR000043 from the National Center for Advancing Translational Sciences (NCATS), and the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program. R.B.D. is a Howard Hughes Medical Institute Investigator.

Competing Interest Statement {#s5f}
----------------------------

The authors have declared no competing interest.
